This indigenously developed enhanced care technology is designed to continuously monitor and detect early signs of deterioration in a patient's condition
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
Exor’s investment in Philips will not result in any share dilution and has been carried out by way of on-market share purchases
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
This innovative product eliminates two manufacturing steps and simplifies equipment setup
Augnito’s AI comprehends all English accents with 99% accuracy
Hampton joins PCC from Accord Healthcare, where he was the President and responsible for accelerating the firm's growth strategy
Subscribe To Our Newsletter & Stay Updated
